Journal article
A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
- Abstract:
-
Background: The development of a new, more effective vaccine against tuberculosis (TB) for use in healthy and HIV-infected adults, children and infants, remains a global health priority. MVA85A is a candidate tuberculosis vaccine designed to enhance immunity to the existing vaccine, Bacillus Calmette-Guerin (BCG). MVA85A entered clinical trials in 2002 and has now progressed to Phase IIb proof-of-concept efficacy trials in infants and HIV-infected adults in Africa. Methods: A detailed analysi...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, pdf, 635.3KB)
-
- Publisher copy:
- 10.1016/j.trivac.2012.07.001
Authors
Funding
University of Oxford
More from this funder
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- Trials in Vaccinology Journal website
- Volume:
- 1
- Pages:
- 27-35
- Publication date:
- 2012-01-01
- DOI:
- EISSN:
-
1879-4378
- ISSN:
-
1879-4378
- Source identifiers:
-
350867
Item Description
- Language:
- English
- Keywords:
- UUID:
-
uuid:cc0cb5a8-50e5-42b1-bc25-f499b0a76aac
- Local pid:
- pubs:350867
- Deposit date:
- 2012-12-19
Terms of use
- Copyright holder:
- Elsevier Ltd
- Copyright date:
- 2012
- Notes:
- Copyright © 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
If you are the owner of this record, you can report an update to it here: Report update to this record